By Frank Prenesti
Date: Thursday 23 Jan 2020
LONDON (ShareCast) - (Sharecast News) - Clinical stage biotech company PureTech Health said it had sold 2.1m shares of its affiliate Karuna Therapeutics for $200m.
PureTech Health said it intended to use the cash to fund operations and advance its clinical stage, wholly-owned pipeline.
The company on Thursday said it would still hold a 20.4% stake in Karuna's and a right to royalty payments on net sales of any commercialised product covered by a license granted by PureTech to Karuna.
Email this article to a friend
or share it with one of these popular networks:
Currency | UK Pounds |
Share Price | 227.00p |
Change Today | 7.00p |
% Change | 3.18 % |
52 Week High | 241.50 |
52 Week Low | 140.40 |
Volume | 393,009 |
Shares Issued | 270.41m |
Market Cap | £613.84m |
Value |
---|
Price Trend |
---|
Income |
---|
Growth |
---|
Strong Buy | 2 |
Buy | 0 |
Neutral | 0 |
Sell | 0 |
Strong Sell | 0 |
Total | 2 |
No dividends found |
Time | Volume / Share Price |
15:23 | 100 @ 227.00p |
15:21 | 1 @ 227.50p |
15:10 | 1 @ 226.72p |
15:10 | 4 @ 227.28p |
15:05 | 1,313 @ 227.01p |
You are here: research